Brugada Syndrome: Overview

The Brugada Syndrome: From Bench to Bedside

Volumn , Issue , 2007, Pages 1-22

  Antzelevitch, Charles ^a   Brugada, Pedro ^b   Borggrefe, Martin ^c   Brugada, Josep ^d   Brugada, Ramon ^a   Corrado, Domenico ^e   Gussak, Ihor ^f   Le Marec, Herve ^g   Nademanee, Koonlawee ^h   Perez Riera, Andrés Ricardo ⁱ   Tan, Hanno ^j,k   Shimizu, Wataru ^l   Schulze Bahr, Eric ^m   Wilde, Arthur A M ^j,k  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b CARDIOVASCULAR CENTER   (Belgium)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^f eResearchTechnology Inc   (United States)

^g CHU de Nantes   (France)

^h Pacific Rim Cardiac Electrophysiology and Research Institute   (United States)

ⁱ FACULDADE DE MEDICINA DO ABC   (Brazil)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^l NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^m UNIVERSITY OF MÜNSTER   (Germany)

more..

Author keywords

Brugada syndrome; Clinical characteristics; Diagnostic criteria; Genetic factors; Risk stratification

Indexed keywords

EID: 33749070756     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470994900.ch1     Document Type: Chapter

References (145)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J. Am. Coll. Cardiol. 1992; 20:1391-1396.
2. Antzelevitch C, Brugada P, Brugada J et al. Brugada syn-drome:a decade of progress. Circ. Res. 2002; 91:1114-1118.
3. Wilde AA,Antzelevitch C, Borggrefe M et al. Proposed diagnostic criteria for the Brugada syndrome. Eur. Heart J. 2002;23:1648-1654.
4. Wilde AA,Antzelevitch C, Borggrefe M et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002;106:2514-2519.
5. Brugada P, Brugada R, Antzelevitch C et al. The Brugada syndrome, in Gussak I, Antzelevitch C, eds.:. Cardiac Repolarization. Bridging Basic and Clinical Sciences. Totowa, NJ, Humana Press,2003:427-446.
6. Brugada P, Brugada J, Brugada R. Arrhythmia induction by antiarrhythmic drugs. Pacing Clin. Electrophysiol. 2000; 23:291-292.
7. Brugada R, Brugada J, Antzelevitch C et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101:510-115.
8. Miyazaki T, Mitamura H, Miyoshi S et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J. Am. Coll. Cardiol. 1996; 27:1061-1070.
9. Antzelevitch C, Brugada R. Fever and the Brugada syndrome. Pacing Clin. Electrophysiol. 2002; 25:1637-1639.
10. Shimizu W,Matsuo K,Takagi M et al. Bodysurface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication ofeighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J. Cardiovasc. Electrophysiol. 2000;11:396-404.
11. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B et al. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur. Heart J. 2001; 22:2290-2296.
12. Alings M, Wilde A. 'Brugada' syndrome: clinical data and suggested pathophysiological mechanism [see comments]. Circulation 1999; 99:666-673.
13. Bezzina C, Veldkamp MW, van Den Berg MP et al. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ. Res. 1999; 85: 1206-1213.
14. Priori SG, Napolitano C, Gasparini M et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families [In Process Citation]. Circulation 2000; 102:2509-2515.
15. Pitzalis MV, Anaclerio M, Iacoviello M et al. QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome. J. Am. Coll. Cardiol. 2003; 42:1632-1637.
16. Smits JP, Eckardt L, Probst V et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J. Am. Coll. Cardiol. 2002;40:350-356.
17. Morita H, Kusano-Fukushima K, Nagase S et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J. Am. Coll. Cardiol. 2002; 40:14-37.
18. Eckardt L, Kirchhof P, Johna R et al. Wolff-Parkinson-White syndrome associated with Brugada syndrome. Pacing Clin. Electrophysiol. 2001;24:1423-1424.
19. Takehara N, Makita N, Kawabe J et al. A cardiac sodium channel mutation identified in Brugada syndrome associated with atrial standstill. J Intern. Med 2004;255:137-142.
20. Kasanuki H, Ohnishi S, Ohtuka M et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997;95:2277-2285.
21. Proclemer A, Facchin D, Feruglio GA et al. Recurrent ventricular fibrillation, right bundle-branch block and persistent ST segment elevation in V1-V3: a new arrhythmia syndrome? A clinical case report (see comments). G. Ital Cardiol. 1993;23:1211-1218.
22. Bjerregaard P, Gussak I, Kotar Sl et al. Recurrent synocope in a patient with prominent J-wave. Am. Heart J. 1994;127:1426-1430.
23. Vatta M, Dumaine R, Varghese G et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum. Mol. Genet. 2002; 11:337-345.
24. Sugai MA. Pathological study on sudden and unexpected death, especially on the cardiac death autopsied by medical examiners in Tokyo. Acta Pathol. Jpn 1959; 9 (suppl):723-752.
25. Nademanee K, Veerakul G, Nimmannit S et al. Arrhyth-mogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96:2595-2600.
26. Corrado D, Basso C, Buja G et al. Right bundle branch block, right precordial ST-segment elevation, and sudden death in young people. Circulation 2001;103:710-717.
27. Ayerza MR, de Zutter M, Goethals M et al. Heart transplantation as last resort against Brugada syndrome. J. Cardiovasc. Electrophysiol. 2002;13:943-944.
28. Remme CA, Wever EFD, Wilde AAM et al. Diagnosis and long-term follow-up of Brugada syndrome in patients with idiopathic ventricular fibrillation. Eur. Heart J. 2001; 22:400-409.
29. Bezzina CR, Rook MB, Groenewegen WA et al. Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ. Res. 2003;92:159-168.
30. Antzelevitch C. Molecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias. Invited Review-NASPE 25th Anniversary. J. Cardiovasc. Electrophysiol 2003;14:1259-1272.
31. Weiss R, Barmada MM, Nguyen T et al. Clinical and molecular heterogeneity in the Brugada syndrome. A novel gene locus on chromosome 3. Circulation 2002;105:707-713.
32. Ahmed F, Li D, Karibe A et al. Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. Circulation 1998;98:2791-2795.
33. Takagi M, Aihara N, Kuribayashi S et al. Localized right ventricular morphological abnormalities detected by electron-beam computed tomography represent ar-rhythmogenic substrates in patients with the Brugada syndrome. Eur.Heart J. 2001; 22:1032-1041.
34. Antzelevitch C. Brugada syndrome: historical perspectives and observations. Eur. Heart J. 2002;23:676-678.
35. Antzelevitch C. Late potentials and the Brugada syndrome. J. Am. Coll. Cardiol. 2002;39:1996-1999.
36. Futterman LG, Lemberg L. Brugada. Am. J. Crit. Care 2001; 10:360-364.
37. Fujiki A, Usui M, Nagasawa H et al. ST segment elevation in the right precordial leads induced with class IC antiar-rhythmic drugs: insight into the mechanism of Brugada syndrome [see comments]. J. Cardiovasc. Electrophysiol. 1999; 10:214-218.
38. Nagase S, Kusano KF, Morita H et al. Epicardial electrogram at the right ventricular outflow tract in patients with Brugada syndrome-using epicardial lead. J. Am. Coll. Cardiol. 2002; 39:1992-1995.
39. Shimizu W, Antzelevitch C, Suyama K et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J. Cardiovasc. Electrophysiol. 2000;11:1320-1329.
40. Gurevitz O, Glikson M. Cardiac re synchronization therapy: a new frontier in the management of heart failure. Isr. Med. Assoc. J. 2003;5:571-575.
41. Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant. J. Cardiovasc. Electrophysiol. 2000;11:95-98.
42. Horigome H, Shigeta O, Kuga K et al. Ventricular fibrillation during anesthesia in association with J waves in the left precordial leads in a child with coarctation of the aorta. J. Electrocardiol. 2003; 36:339-343.
43. Brugada J, Brugada R, Antzelevitch C et al. Long-term follow-up of individuals with the electrocardiographic pattern ofright bundle-branch block and ST-segment elevation in precordial leads V(1) toV(3).Circulation2002; 105:73-78.
44. Priori SG, Napolitano C, Gasparini M et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002;105:1342-1347.
45. Atarashi H, Ogawa S. For the idiopathic ventricular fibrillation investigators: new ECG criteria for high-risk Bru-gada syndrome. Circ. J. 2003;67:8-10.
46. Morita H, Takenaka-Morita S, Fukushima-Kusano K et al. Risk stratification for asymptomatic patients with Brugada syndrome. Circ. J. 2003;67:312-316.
47. Kanda M, Shimizu W, Matsuo K et al. Electrophysiologic characteristics and implications of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. J. Am. Coll. Cardiol. 2002; 39:1799-1805.
48. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003;108:3092-3096.
49. Chen Q, Kirsch GE, Zhang D et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998; 392:293-296.
50. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J. Cardiovasc. Electrophysiol. 2001; 12:268-272.
51. Balser JR. The cardiac sodium channel: gating function and molecular pharmacology. J. Mol. Cell. Cardiol. 2001; 33:599-613.
52. Tan HL, Bezzina CR, Smits JP et al. Genetic control of sodium channel function. Cardiovasc. Res. 2003;57:961-973.
53. Dumaine R, Towbin JA, Brugada P et al. Ionic mechanisms responsible for the electrocardiographic phenotype ofthe Brugada syndrome are temperature dependent. Circ. Res. 1999;85:803-809.
54. Schulze-Bahr E, Eckardt L, Breithardt G et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Human Mut. online. 2003.
55. Antzelevitch C, Sicouri S, Litovsky SH et al. Heterogeneity within the ventricular wall: electrophysiology and pharmacology of epicardial, endocardial and M cells. Circ. Res. 1991; 69:1427-1449.
56. Krishnan SC, Antzelevitch C. Sodium channel blockade produces opposite electrophysiologic effects in canine ventricular epicardium and endocardium. Circ. Res. 1991; 69:277-291.
57. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 Reentry. Circulation 1993;87:562-572.
58. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 1996;93:372-379.
59. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J. Cardiovasc. Electrophysiol. 2001; 12:268-272.
60. Gussak I,Antzelevitch C, Bjerregaard P et al. The Brugada syndrome: clinical, electrophysiological and genetic aspects. J. Am. Coll. Cardiol. 1999;33:5-15.
61. Lukas A, Antzelevitch C. Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epi-cardium exposed to simulated ischemia. The antiar-rhythmic effects of 4-aminopyridine. Cardiovasc. Res. 1996;32:593-603.
62. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999; 100:1660-1666.
63. Kurita T, Shimizu W, Inagaki M et al. The electrophysio-logic mechanism of ST-segment elevation in Brugada syndrome. J. Am. Coll. Cardiol. 2002; 40:330-334.
64. Antzelevitch C, Dumaine R. Electrical heterogeneity in the heart: physiological, pharmacological and clinical implications. In Page E, Fozzard HA, Solaro RJ, eds. Handbook of Physiology. The Heart. New York: Oxford University Press, 2001:654-692.
65. Di Diego JM, Cordeiro JM, Goodrow RJ et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002;106:2004-2011.
66. Babaliaros VC, Hurst JW. Tricyclic antidepressants and the Brugada syndrome: an example of Brugada waves appearing after the administration ofdesipramine. Clin. Cardiol. 2002;25:395-398.
67. Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N. Engl. J. Med. 2002; 346:1591-1592.
68. Tada H, Sticherling C, Oral H et al. Brugada syndrome mimicked by tricyclic antidepressant overdose. J. Cardio-vasc. Electrophysiol. 2001; 12: 275.
69. Pastor A, Nunez A, Cantale C et al. Asymptomatic Bruga-da syndrome case unmasked during dimenhydrinate infusion. J. Cardiovasc. Electrophysiol. 2001; 12:1192-1194.
70. Ortega-Carnicer J, Bertos-Polo J, Gutierrez-Tirado C. Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion. J. Electrocardiol. 2001; 34:345-349.
71. Nogami A, Nakao M, Kubota S et al. Enhancement of J-ST-segment elevation by the glucose and insulin test in Brugada syndrome. Pacing Clin. Electrophysiol. 2003;26:332-337.
72. Araki T, Konno T, Itoh H et al. Brugada syndrome with ventricular tachycardia and fibrillation related to hypokalemia. Circ. J. 2003; 67:93-95.
73. Noda T, Shimizu W, Taguchi A et al. ST-segment elevation and ventricular fibrillation without coronary spasm by intracoronary injection of acetylcholine and/or er-gonovine maleate in patients with Brugada syndrome. J. Am. Coll. Cardiol. 2002; 40:1841-1847.
74. Mizumaki K, Fujiki A, Tsuneda T et al. Vagal activity modulates spontaneous augmentation of ST elevation in daily life of patients with Brugada syndrome. J. Cardiovasc. Electrophysiol. 2004; 15:667-673.
75. Wichter T, Matheja P, Eckardt L et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002; 105:702-706.
76. Litovsky SH, Antzelevitch C. Differences in the electro-physiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol.A direct effect ofacetylcholine in ventricular myocardium. Circ. Res. 1990;67:615-627.
77. Nimmannit S, Malasit P, Chaovakul V et al. Pathogenesis of sudden unexplained nocturnal death (lai tai) and endemic distal renal tubular acidosis. Lancet 1991;338:930-932.
78. Gonzalez Rebollo G, Madrid H, Carcia A et al. Reccurrent ventricular fibrillation during a febrile illness in a patient with the Brugada syndrome. Rev. Esp. Cardiol. 2000;53:755-757.
79. Madle A, Kratochvil Z, Polivkova A. [The Brugada syndrome]. Vnitr. Lek. 2002;48:255-258.
80. Saura D, Garcia-Alberola A, Carrillo P et al. Brugada-like electrocardiographic pattern induced by fever. Pacing Clin. Electrophysiol. 2002;25:856-859.
81. Porres JM, Brugada J, Urbistondo V et al. Fever unmasking the Brugada syndrome. Pacing Clin. Electrophysiol. 2002; 25:1646-1648.
82. Kum L, Fung JWH, Chan WWL et al. Brugada syndrome unmasked by febrile illness. Pacing Clin. Electrophysiol. 2002; 25:1660-1661.
83. Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J. Electrocardiol. 2000; 33 Suppl: 41-47.
84. Brugada P, Brugada R, Brugada J et al. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am. J. Cardiol. 1999; 83: 98D-100D.
85. Haissaguerre M, Extramiana F, Hocini M et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003;108:925-928.
86. rA marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457-460.
87. Antzelevitch C, Brugada P, Brugada J et al. The Brugada Syndrome. Armonk, NY: Futura Publishing Company, Inc., 1999:1-99.
88. Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: is ICD the only therapeutic option. Pacing Clin. Electrophysiol. 2002;25:1634-1640.
89. Alings M, Dekker L, Sadee A et al. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin. Electrophysiol. 2001;24:1420-1422.
90. Suzuki H, Torigoe K, Numata O et al. Infant case with a malignant form of Brugada syndrome. J. Cardiovasc. Electrophysiol. 2000; 11:1277-1280.
91. Tanaka H, Kinoshita O, Uchikawa S et al. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin. Electrophysiol. 2001; 24:1293-1294.
92. Belhassen B, Viskin S, Fish R et al. Effects ofelectrophysi-ologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome [see comments]. J. Cardiovasc. Electrophysiol. 1999; 10:1301-1312.
93. Tsuchiya T, Ashikaga K, Honda T et al. Prevention ofven-tricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J. Cardiovasc. Electrophysiol. 2002; 13:698-701.
94. Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions other than acute myocardial infarction. N. Engl. J. Med. 2003; 349:2128-2135.
95. Myers GB. Other QRS-T patterns that may be mistaken for myocardial infarction. IV. Alterations in blood potassium; myocardial ischemia; subepicardial myocarditis; distortion associated with arrhythmias.Circulation1950; 2: 75-93.
96. Abbott JA, Cheitlin MD. The nonspecific camel-hump sign. JAMA 1976; 235:413-414.
97. Hersch C. Electrocardiographic changes in head injuries. Circulation 1961;23:853-860.
98. Perloff JK, Henze E, Schelbert HR. Alterations in regional myocardial metabolism, perfusion, and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Circulation 1984; 69:33-42.
99. Read DH, Harrington DD. Experimentally induced thiamine deficiency in beagle dogs: clinical observations. Am. J. Vet. Res. 1981; 42:984-991.
100. Merrill JP, Levine HD, Somerville W et al. Clinical recognition and treatment of acute potassium intoxication. Ann. Intern. Med. 1950;33:797-830.
101. Ortega-Carnicer J, Benezet J, Ruiz-Lorenzo F et al. Transient Brugada-type electrocardiographic abnormalities in renal failure reversed by dialysis. Resuscitation 2002; 55:215-219.
102. Douglas PS, Carmichael KA, Palevsky PM. Extreme hypercalcemia and electrocardiographic changes. Am. J. Cardiol. 1984;54:674-675.
103. Sridharan MR, Horan LG. Electrocardiographic J wave of hypercalcemia. Am. J. Cardiol. 1984;54:672-673.
104. Corrado D, Nava A,Buja G et al. Familial cardiomyopathy underlies syndrome of right bundle branch block, ST segment elevation and sudden death [see comments]. J. Am. Coll. Cardiol. 1996;27:443-448.
105. Osborn JJ. Experimental hypothermia: respiratory and blood pH changes in relation to cardiac function. Am. J. Physiol. 1953; 175:389-398.
106. Noda T, Shimizu W, Tanaka K et al. Prominent J wave and ST segment elevation: serial electrocardiographic changes in accidental hypothermia. J. Cardiovasc. Electrophysiol. 2003;14:223.
107. Tarin N, Farre J, Rubio JM et al. Brugada-like electrocardiographic pattern in a patient with a mediastinal tumor. Pacing Clin. Electrophysiol. 1999;22:1264-1266.
108. Tomcsanyi J, Simor T, Papp L. Images in cardiology. Haemopericardium and Brugada-like ECG pattern in rheumatoid arthritis. Heart2002; 87:234.
109. Krishnan SC, Josephson ME. ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J. Cardiovasc. Electrophysiol. 1998; 9:1167-1172.
110. Fujiki A, Usui M, Nagasawa H et al. ST segment elevation in the right precordial leads induced with class IC antiar-rhythmic drugs: insight into the mechanism of Brugada syndrome [see comments]. J. Cardiovasc. Electrophysiol. 1999; 10:214-218.
111. Gasparini M, Priori SG, Mantica M et al. Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin. Electrophysiol. 2003;26:338-341.
112. Takenaka S, Emori T, Koyama S et al. Asymptomatic form of Brugada syndrome. Pacing Clin. Electrophysiol. 1999;22:1261-1263.
113. Shimizu W, Aiba T, Kurita T et al. Paradoxic abbreviation of repolarization in epicardium of the right ventricular outflow tract during augmentation of Brugada-type ST segment elevation. J. Cardiovasc. Electrophysiol. 2001;12:1418-1421.
114. Matana A, Goldner V, Stanic K et al. Unmasking effect of propafenone on the concealed form of the Brugada phenomenon. Pacing Clin. Electrophysiol. 2000; 23:416-418.
115. Rolf S, Bruns HJ, Wichter T et al. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur. Heart J. 2003;24:1104-1112.
116. Tada H, Nogami A, Shimizu W et al. ST segment and T wave alternans in a patient with Brugada syndrome. Pacing Clin. Electrophysiol. 2000; 23:413-415.
117. Matsuo K, Shimizu W, Kurita T et al. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J. Cardiovasc. Electrophysiol. 1998; 9:508-512.
118. Bolognesi R, Tsialtas D,Vasini P et al. Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am. J. Cardiol. 1997; 79:242-245.
119. Rouleau F, Asfar P, Boulet S et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J. Cardiovasc. Electrophysiol. 2001;12:61-65.
120. Antzelevitch C. The Brugada syndrome. J. Cardiovasc. Electrophysiol. 1998;9:513-516.
121. Pastor A, Nunez A, Cantale C et al. Asymptomatic Bruga-da syndrome case unmasked during dimenhydrinate infusion. J. Cardiovasc. Electrophysiol. 2001;12:1192-1194.
122. Littmann L, Monroe MH, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin. Proc. 2000; 75:845-849.
123. Vatta M, Dumaine R, Antzelevitch C et al. Novel mutations in domain I of SCN5A cause Brugada syndrome. Mol. Genet. Metab. 2002; 75:317-324.
124. Wan X, Chen S, Sadeghpour A et al. Accelerated inactivation in a mutant Na(+) channel associated with idiopathic ventricular fibrillation. Am. J. Physiol. Heart Circ. Physiol. 2001; 280: H354-H360.
125. Mok NS, Priori SG, Napolitano C et al. A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc. Electrophysiol. 2003; 14:407-411
126. Potet F, Mabo P, Le Coq G et al. Novel brugada SCN5A mutation leading to ST segment elevation in the inferior or the right precordial leads. J. Cardiovasc. Electrophysiol. 2003; 14:200-203.
127. Baroudi G, Acharfi S, Larouche C et al. Expression and intracellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome. Circ. Res. 2002; 90: E11-E16.
128. Wan X, Wang Q, Kirsch GE. Functional suppression of sodium channels by beta(1)-subunits as a molecular mechanism of idiopathic ventricular fibrillation [In Process Citation]. J. Mol. Cell. Cardiol. 2000;32:1873-1884.
129. Kyndt F, Probst V, Potet F et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104:3081-3086.
130. Deschenes I, Baroudi G, Berthet M et al. Electrophysio-logical characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardiovasc. Res. 2000;46:55-65.
131. Baroudi G, Pouliot V, Denjoy I et al. Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). Circ. Res. 2001; 88: E78-E83.
132. Rook MB,Alshinawi CB, Groenewegen WA et al. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc. Res. 1999; 44:507-517.
133. Shirai N, Makita N, Sasaki K et al. A mutant cardiac sodium channel with multiple biophysical defects associated with overlapping clinical features of Brugada syndrome and cardiac conduction disease. Cardiovasc. Res. 2002;53:348-354.
134. Baroudi G, Carbonneau E, Pouliot V et al. SCN5A mutation (T1620M) causing Brugada syndrome exhibits different phenotypes when expressed in Xenopus oocytes and mammalian cells. FEBS Lett. 2000; 467:12-16.
135. Wang DW, Makita N, Kitabatake A et al. Enhanced Na(+) channel intermediate inactivation in Brugada syndrome. Circ. Res. 2000; 87: E37-E43.
136. Kiehn J, Karle C, Thomas D et al. HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways. J Biol. Chem. 1998;273:25285-25291.
137. Akai J, Makita N, Sakurada H et al. A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. FEBS Lett. 2000; 479:29-34.
138. Veldkamp MW, Viswanathan PC, Bezzina C et al. Two distinct congenital arrhythmias evoked by a multidys-functional Na(+) channel. Circ. Res. 2000; 86: E91-E97.
139. Viswanathan PC, Bezzina CR, George AL, Jr. et al. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.Circulation2001; 104:1200-1205.
140. Baroudi G, Chahine M. Biophysical phenotypes of SCN5A mutations causing long QT and Brugada syndromes. FEBS Lett. 2000; 487:224-228.
141. Rivolta I, Abriel H, Tateyama M et al. Inherited Brugada and LQT-3 syndrome mutations ofa single residue ofthe cardiac sodium channel confer distinct channel and clinical phenotypes. J. Biol. Chem. 2001; 276:30623-30630.
142. Tan HL, Kupershmidt S, Zhang R et al. A calcium sensor in the sodium channel modulates cardiac excitability. Nature 2002; 415:442-447.
143. Tan HL. Biophysical analysis of mutant sodium channels in Brugada syndrome. In: Antzelevitch C, Brugada P, eds. The Brugada Syndrome. Elmsford: Blackwell Publishing, 2004.
144. Antzelevitch C. The Brugada syndrome. Diagnostic criteria and cellular mechanisms. Eur. Heart J. 2001;22:356-363.
145. Nademanee K, Veerakul G, Schwab M. Predisposing factors in the Brugada syndrome. In: Antzelevitch C, Brugada P, eds. The Brugada Syndrome. Elmsford, Blackwell Publishing, 2004.